Anti-CXCR3 treatment decreases pulmonary injury in NY1DD mice. (A) Representative images of H&E-stained lungs from C57BL/6 or NY1DD mice treated with goat serum and NY1DD mice treated with goat anti-CXCR3. Scale bar represents 200 μm. (B) Histopathologic scores (0-8, see “Methods”) by analysis of H&E-stained mouse lungs. (C-D) Anti-CXCR3-treated NY1DD animals have decreased vascular permeability and increased arterial oxygen saturation compared with serum-treated NY1DD mice. (E) Anti-CXCR3-treated NY1DD mice have improved breathing (increased tidal volume and decreased frequency of breathing) compared with serum-treated NY1DD mice. Data were analyzed by one-way ANOVA with Neuman-Keuls posttesting. Breathing parameters were analyzed by 2-way ANOVA with Bonferroni posttesting. Histologic grading was analyzed with a nonparametric Kruskal-Wallis test with Dunn posttesting (*P < .05). EBD, Evans blue dye; SO2 indicates arterial oxygen saturation; FOB, frequency of breathing; and TV, tidal volume.
